SUMMARY OF PRODUCT CHARACTERISTICS

1 NAME OF THE MEDICINAL PRODUCT
Mydriate 1.0% Eye Drops
Cyclopentolate Hydrochloride 1.0% w/v Eye Drops, Solution

2. QUALITATIVE AND QUANTITATIVE COMPOSITION
Cyclopentolate Hydrochloride BP 1.0 % w/v.

3. PHARMACEUTICAL FORM
Eye drops.

4. CLINICAL PARTICULARS

4.1. Therapeutic Indications
(i) Diagnostic purposes for fundoscopy and cycloplegic refraction.
(ii) Dilating the pupil in inflammatory conditions of the iris and uveal tract.

4.2. Posology and Method of Administration

(i) Refraction / Fundoscopy
Adults (and the elderly):
One drop of 0.5 % solution instilled into the eye, repeated after 15 minutes if necessary, approximately 40 minutes before examination.

Deeply pigmented eyes may require the use of a 1 % solution.

NB: Maximum effect is reached after 30-60 minutes,

Children 6-16 years:
One drop of 1 % solution instilled into the eye, repeated after 15 minutes if necessary, approximately 40 minutes before examination.

Children under 6 years:
One or two drops of 1 % solution instilled into the eye, repeated after 15 minutes if necessary, approximately 40 minutes before examination.

(ii) For Uveitis, Iritis and Iridocyclitis:

Adults and the elderly:
One or two drops of 0.5 % solution instilled into the eye up to 4 times daily or as required.

Deeply pigmented eyes may require the use of a 1 % solution.

Children:
At the discretion of the physician

Do not use during the first three months of life due to possible association between the cycloplegia produced and the development of amblyopia and also the increased risks of systemic toxicity in neonates.

Cycloplegia following administration is quick in onset and short-lived. Maximal cycloplegia is achieved within 15 - 45 minutes of instillation and lasts on average about 20 minutes. Recovery normally takes place in about 4 hours, but very occasionally some effect persists for up to 24 hours.

Mydriasis is produced very rapidly and an average pupil diameter of 7 mm is usually reached 15 - 30 minutes after instillation of one drop of 0.5 % solution. Complete recovery from the mydriatic effect generally occurs spontaneously in not more than 20 hours.

No specific information on the use of this product in the elderly is available. Clinical trials have included patients over 65 years and no adverse reactions specific to this age group have been reported.

4.3. Contra-Indications

(i) Use in narrow-angle glaucoma or those with a tendency towards glaucoma e.g. patients with a shallow anterior chamber.

(ii) Hypersensitivity to cyclopentolate hydrochloride, benzalkonium chloride or any other components of the formulation.

(iii) This preparation contains benzalkonium chloride and should not be used whilst soft contact lenses are being worn.

(iv) Use in patients with paralytic ileus.

(v) Use in children with organic brain syndromes, including congenital or neuro-developmental abnormalities, particularly those predisposing to epileptic seizures.
4.4. **Special Warnings and Special Precautions for Use**

Because of the risk of precipitating angle-closure glaucoma in the elderly and others prone to raised intraocular pressure, an estimate of the depth of the anterior chamber should be made before use, particularly if therapy is likely to be intense or protracted.

Caution should be observed when drugs of this group are administered to patients with prostatic enlargement, coronary insufficiency or cardiac failure, or ataxia. Atropine-like effects have been reported as side-effects.

Extreme caution is advised for use in children and individuals susceptible to belladonna alkaloids because of the increased risk of systemic toxicity.

Patients should be warned of the oral toxicity of this preparation, and advised to wash their hands after use. If accidentally swallowed, patients should be advised to seek medical attention.

Use with caution in an inflamed eye as the hyperaemia greatly increases the rate of systemic absorption through the conjunctiva.

To reduce systemic absorption the lacrimal sac should be compressed at the medial canthus by digital pressure for at least two minutes after instillation of the drops.

4.5. **Interactions with other Medicinal Products and other Forms of Interaction**

The effects of anti-muscarinic agents may be enhanced by the concomitant administration of other drugs with anti-muscarinic properties such as some antihistamines, butyrophenones, phenothiazines, tricyclic antidepressants and amantadine.

4.6. **Pregnancy and Lactation**

There is insufficient evidence as to drug safety in pregnancy and lactation. This product should not be used during pregnancy unless it is considered essential by a physician.

4.7. **Effects on Ability to Drive and Use Machines**
May cause blurred vision, difficulty in focusing and sensitivity to light. Patients should be warned not to drive or engage in other hazardous activities (including climbing ladders and scaffolding) unless vision is clear. Complete recovery from the effects of Mydrilate Eye Drops may take up to 24 hours.

4.8. Undesirable Effects

(i) **Local:**
Increased intraocular pressure, transient stinging, and sensitivity to light secondary to pupillary dilation. Prolonged administration may lead to local irritation, hyperaemia, oedema and conjunctivitis.

(ii) **Systemic:**
Systemic anticholinergic toxicity is manifested by dryness of the mouth, flushing, dryness of the skin, bradycardia followed by tachycardia with palpitations and arrhythmias, urinary urgency, difficulty and retention, reduction in the tone and motility of the gastrointestinal tract leading to constipation.

(iii) Vomiting, giddiness and staggering may occur, a rash may be present in children, abdominal distension in infants. Psychotic reactions, behavioural disturbances and cardio-respiratory collapse may occur in children.

4.9. Overdose

Systemic toxicity may occur following topical use, particularly in children. It is manifested by flushing and dryness of the skin (a rash may be present in children), blurred vision, a rapid and irregular pulse, fever, abdominal distension in infants, convulsions and hallucinations and the loss of neuromuscular co-ordination.

Treatment is supportive (there is no evidence that physostigmine is superior to supportive management). In infants and small children the body surface must be kept moist. If accidentally ingested, induce emesis or perform gastric lavage.

5. PHARMACOLOGICAL PROPERTIES

5.1. Pharmacodynamic Properties

Cyclopentolate is an anti-muscarinic agent used topically in the eye as a mydriatic and cycloplegic. The effects are similar to those of atropine, but with a more rapid onset and a shorter duration of action.
5.2. Pharmacokinetic Properties

None stated.

5.3. Pre-clinical Safety Data

None stated.

6. PHARMACEUTICAL PARTICULARS

6.1. List of Excipients

Boric acid
Potassium chloride
Benzalkonium chloride solution
Purified water.

6.2. Incompatibilities

None stated.

6.3. Shelf Life

2 years.

6.4. Special Precautions for Storage

Store at 2-8 °C. Refrigerate, do not freeze. Protect from light. Do not dilute or dispense from any container other than the original bottle. Discard one month after opening.
6.5 Nature and contents of container
5 ml dropper bottle of 1.0% solution.
Bottle: LDPE, natural colour.
Cap: White plastic.

6.6. Instructions for Use, Handling and Disposal

When using the product for the first time, screw down the cap firmly on the bottle to pierce the seal at the tip of the plastic nozzle and unscrew the cap for use.

7 MARKETING AUTHORISATION HOLDER
Intrapharm Laboratories Limited
The Courtyard Barns
Choke Lane
Cookham Dean
Maidenhead
Berks SL6 6PT
United Kingdom

8. MARKETING AUTHORISATION NUMBER(S)
PL 17509/0008

9. DATE OF FIRST AUTHORISATION/RENEWAL OF AUTHORISATION
8 August 2001

10 DATE OF REVISION OF THE TEXT
16/04/2012